PI-1840 - CAS 1401223-22-0
Catalog number: 1401223-22-0
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C22H26N4O3
Molecular Weight:
394.47
COA:
Inquire
Targets:
Proteasome
Description:
PI-1840 potently inhibits proteasomal CT-L activity with IC50 of 0.37 μM in intact human MDA-MB-468 cancer cells, and inhibits proliferation/survival of human MDA-MB-468 cells.
Publication citing BOC Sciences Products
1. Characterization of histone acylations links chromatin modifications with metabolism
2. Rapid liquid chromatography tandem mass spectrometry method for targeted quantitation of human performance metabolites in saliva
3. Crystallization of star-shaped and linear poly (l-lactide)s
4. Flavonoids from Sideritis species: human monoamine oxidase (hMAO) inhibitory activities, molecular docking studies and crystal structure of xanthomicrol
5. Therapeutic Drug Monitoring of Teicoplanin Using an LC-MS/MS Method: Analysis of 421 Measurements in a Naturalistic Clinical Setting
6. Deletion of HP1γ in cardiac myocytes affects H4K20me3 levels but does not impact cardiac growth

>> More

Purity:
>98%
Synonyms:
PI-1840; PI 1840; PI1840
MSDS:
Inquire
InChIKey:
ZVVXAODXPVWGMF-UHFFFAOYSA-N
InChI:
InChI=1S/C22H26N4O3/c1-4-6-17-8-10-19(11-9-17)28-15-21(27)26(16(2)3)14-20-24-22(25-29-20)18-7-5-12-23-13-18/h5,7-13,16H,4,6,14-15H2,1-3H3
Canonical SMILES:
CCCC1=CC=C(C=C1)OCC(=O)N(CC2=NC(=NO2)C3=CN=CC=C3)C(C)C
1.Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity.
Kazi A1, Ozcan S, Tecleab A, Sun Y, Lawrence HR, Sebti SM. J Biol Chem. 2014 Apr 25;289(17):11906-15. doi: 10.1074/jbc.M113.533950. Epub 2014 Feb 25.
The proteasome inhibitor bortezomib is effective in hematologic malignancies such as multiple myeloma but has little activity against solid tumors, acts covalently, and is associated with undesired side effects. Therefore, noncovalent inhibitors that are less toxic and more effective against solid tumors are desirable. Structure activity relationship studies led to the discovery of PI-1840, a potent and selective inhibitor for chymotrypsin-like (CT-L) (IC50 value = 27 ± 0.14 nm) over trypsin-like and peptidylglutamyl peptide hydrolyzing (IC50 values >100 μm) activities of the proteasome. Furthermore, PI-1840 is over 100-fold more selective for the constitutive proteasome over the immunoproteasome. Mass spectrometry and dialysis studies demonstrate that PI-1840 is a noncovalent and rapidly reversible CT-L inhibitor. In intact cancer cells, PI-1840 inhibits CT-L activity, induces the accumulation of proteasome substrates p27, Bax, and IκB-α, inhibits survival pathways and viability, and induces apoptosis.
2.Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors.
Ozcan S1, Kazi A, Marsilio F, Fang B, Guida WC, Koomen J, Lawrence HR, Sebti SM. J Med Chem. 2013 May 23;56(10):3783-805. doi: 10.1021/jm400221d. Epub 2013 May 13.
Screening of the 50000 ChemBridge compound library led to the identification of the oxadiazole-isopropylamide 1 (PI-1833) which inhibited chymotrypsin-like (CT-L) activity (IC50 = 0.60 μM) with little effects on the other two major proteasome proteolytic activities, trypsin-like (T-L) and postglutamyl-peptide-hydrolysis-like (PGPH-L). LC-MS/MS and dialysis show that 1 is a noncovalent and rapidly reversible CT-L inhibitor. Focused library synthesis provided 11ad (PI-1840) with CT-L activity (IC50 = 27 nM). Detailed SAR studies indicate that the amide moiety and the two phenyl rings are sensitive toward modifications. Hydrophobic residues, such as propyl or butyl in the para position (not ortho or meta) of the A-ring and a m-pyridyl group as B-ring, significantly improve activity. Compound 11ad (IC50 = 0.37 μM) is more potent than 1 (IC50 = 3.5 μM) at inhibiting CT-L activity in intact MDA-MB-468 human breast cancer cells and inhibiting their survival.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Proteasome Products

CAS 134381-21-8 Epoxomicin

Epoxomicin
(CAS: 134381-21-8)

Epoxomicin is a potent anti-tumor agent isolated from Actinomycetes that is used as a selective and irreversible inhibitor of the 20S proteasome. It inhibits pr...

CAS 158442-41-2 PSI

PSI
(CAS: 158442-41-2)

PSI is a drug that blocks the action of proteasomes, protein complexes that degrade unneeded and damaged proteins. It causes dopaminergic cell death in vitro an...

CAS 179324-69-7 Bortezomib (PS-341)

Bortezomib (PS-341)
(CAS: 179324-69-7)

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM.

CAS 179528-45-1 PD 150606

PD 150606
(CAS: 179528-45-1)

PD 150606 is a selective, cell-permeable inhibitor of calpains (Ki = 0.21 μM for μ-calpain (calpain-1) and 0.37 μM for m-calpain (calpain-2)). It targets the ca...

CAS 179461-52-0 PD 151746

PD 151746
(CAS: 179461-52-0)

PD 151746 is a selective, cell-permeable calpain inhibitor with Ki of 0.26 μM for μ-Calpain, about 20-fold selectivity over m-calpain.

CAS 1617495-03-0 RA190

RA190
(CAS: 1617495-03-0)

RA190, a bis-benzylidine piperidon, is a novel potent and selective inhibitor of proteasome ubiquitin receptor RPN13/ADRM1. RA190 stabilized targets of human pa...

Ixazomib citrate
(CAS: 1239908-20-3)

The citrate salt form of Ixazomib which is a proteasome inhibitor. It is considered a rollover Phase II trial against multiple myeloma, amyloidosis and lymphoma...

CAS 1401223-22-0 PI-1840

PI-1840
(CAS: 1401223-22-0)

PI-1840 potently inhibits proteasomal CT-L activity with IC50 of 0.37 μM in intact human MDA-MB-468 cancer cells, and inhibits proliferation/survival of human M...

Chemical Structure

CAS 1401223-22-0 PI-1840

Quick Inquiry

Verification code

Featured Items